Abstract
AimsWe investigated the prevalence of severe asthma, its comorbidities, and especially the use of oral corticosteroid (OCS) therapy in patients with severe asthma.MethodsPooled data from 3 961 429 patients insured (with statutory health insurance) during the year 2015 were analysed. Prevalence rates of severe asthma and its OCS-associated comorbidities in patients on high-dosage (HD) inhaled corticosteroid (ICS) in combination with a long-acting β agonist (LABA) therapy were compared with those of patients who were also treated with OCSs.ResultsThe asthma prevalence was 7.3%, of which 8.7% (0.6% absolute) were treated with HD-ICS/LABAs. Of these, 33.6% received additional OCSs with calculated dosages between 0.9 and 9.1 mg·day−1. More than 80% of patients on HD-ICS/LABAs had at least one comorbidity. Disorders of the heart (67.5%), metabolism/ nutrition (51.4%), psychiatric disorders (36.0%), skeletal muscle/connective tissue and bone disorders (20.3%), and eye disorders (20.0%) were predominant. The prevalence of these disorders increased for patients also receiving OCS therapy, depending on the length of treatment. Mean therapy costs ranged from €4266 per patient without OCS therapy to €11 253 per patient on long-term OCS treatment. The largest share of costs was attributable to inpatient care.ConclusionThe analyses show that OCSs are frequently prescribed in patients receiving HD-ICS/LABAs because of severe asthma and are they are frequently associated with adverse effects commonly reported with steroid usage. These data support a necessary change in severe asthma treatment, which is reflected in current treatment guidelines.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference27 articles.
1. Global Asthma Network . Global Asthma Report 2018 . www.globalasthmareport.org/ Date last updated: 2018. Date last accessed: March 11, 2019.
2. Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention 2018 . www.ginasthma.org Date last updated: 2018. Date last accessed: March 11, 2019.
3. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
4. Treatment of severe asthma: entering the era of targeted therapy;van Buul;Expert Opin Biol Ther,2015
5. The prevalence of severe refractory asthma
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献